Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 21, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
Myelodysplastic SyndromeAcute Leukemia
Interventions
DRUG

Reduced ATG plus mini PTCy

The conditioning protocol comprises cytarabine (Ara-C) (4 g/m2/day, days -9), busulfan (Bu) (3.2 mg/kg/day, days -8 to -6), cyclophosphamide (Cy) (1.8 g/m2/kg, days -5 and -4), simustine (250 mg/m2, day -3) and r-ATG (total 7.5mg/kg ,from days -5 to -2). Mini PTCy 14.5mg/kg/day will be given on day +3 and +4.

Trial Locations (1)

Unknown

RECRUITING

Peking University People'S Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER